Find verified Futibatinib API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Futibatinib for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Futibatinib API.
Alternate Names: Lytgobi,futibatinibum
CAS No: 1448169-71-8
PubChem CID: 71621331
Mol Formula: C22H22N6O3
Mol Weight: 418.40 g/mol
IUPAC Name: 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
Therapeutic use: Anti-cancer agents
Drug Class: Kinase inhibitors, Tyrosine Kinase Inhibitors
Commercial / Development Status: Commercial
Source / Manufacturing Origin: Synthetic
API Description: Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies. As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma. On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.
